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Summary
More than 50 interventions have been used to treat hidradenitis suppurativa
(HS), and so therapy decisions can be challenging. Our objective was to summa-
rize and appraise randomized controlled trial (RCT) evidence for HS interventions
in adults. Searches were conducted in Medline, Embase, CENTRAL, LILACS, five
trials registers and abstracts from eight dermatology conferences until 13 August
2015. Two review authors independently assessed study eligibility, extracted data
and assessed methodological quality. Primary outcomes were quality of life and
adverse effects of the interventions. Twelve trials, from 1983 to 2015, investigat-
ing 15 different interventions met our inclusion criteria. The median trial dura-
tion was 16 weeks and the median number of participants was 27. Adalimumab
40 mg weekly improved the Dermatology Life Quality Index (DLQI) by 40
points, which equates to the minimal clinically important difference for the scale,
compared with placebo (95% confidence interval 65 to 15 points). Evidence
quality was reduced to ‘moderate’ because the results are based on only a single
study. Adalimumab 40 mg every other week was ineffective in a meta-analysis of
two studies comprising 124 participants. Infliximab 5 mg kg1 improved the
DLQI score by 84 points after 8 weeks in a moderate-quality study completed
by 33 of 38 participants. Etanercept 50 mg twice weekly was ineffective. Inclu-
sion of a gentamicin sponge prior to primary closure did not improve outcomes.
Other interventions, including topical and oral antibiotics, were investigated by
relatively small studies, preventing treatment recommendations due to impreci-
sion. More, larger RCTs are required to investigate most HS interventions, partic-
ularly oral treatments and surgical therapy. Moderate-quality evidence suggests
that adalimumab given weekly and infliximab are effective, whereas adalimumab
every other week is ineffective.
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What’s already known about this topic?
• Many interventions have been tried for hidradenitis suppurativa (HS).
• Evidence supporting the choice of intervention for HS is often limited.
What does this study add?
• Moderate-quality evidence suggests that adalimumab given weekly and infliximab
are effective, whereas adalimumab every other week is ineffective.
• There are very limited or no randomized controlled trial data in HS for antibiotic ther-
apy, retinoids, oral immunomodulators or the timing and type of surgery to perform.
Hidradenitis suppurativa (HS), also known as acne inversa, is a
chronic inflammatory skin disease characterized by painful nod-
ules, sinuses and scarring in flexural locations.1 Treatment of HS
can be challenging, and more than 50 interventions have been
reported in the literature, often supported by only low-quality
evidence. As a result, it can be difficult for clinicians to make evi-
dence-based decisions in partnership with patients.
In 2011 a Cochrane review team was assembled to under-
take a review of all medical and surgical interventions for HS,
restricting the systematic search for trial data to only the high-
est-quality evidence, in the form of randomized controlled tri-
als (RCTs). The quality of the RCTs was also assessed using
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) methodology, incorporated into summary
of findings tables.2 The GRADE system evaluates the trial data
for a particular intervention in terms of each key outcome pre-
determined by the review team, and can be used to convert
evidence quality and effect sizes into strengths of recommen-
dation. The full review was recently published in the Cochrane
Library and is summarized here.3
Methods
The protocol for our Cochrane review was prepublished in
the Cochrane Library, and any deviations from the protocol
are highlighted in the final published review.3 Our inclusion
criteria to select relevant studies were RCTs of any HS inter-
vention involving male and female adults of any age and eth-
nicity. Only the first phase of crossover trials was included to
avoid carry-over effects of interventions with a long duration
of action. Primary and secondary outcomes are given in
Table 1 and were selected following discussion between the
clinicians and consumer author on the review team. In keep-
ing with Cochrane guidelines,4 one primary outcome was
selected to assess treatment benefit, namely quality of life,
and one to assess potential harm, in this case the adverse
effects of interventions. Adverse effects were defined as seri-
ous if they resulted in death, hospital admission or a longer
hospital stay.
Search strategies
Using the terms ‘acne inversa’, ‘hidradenitis suppurativa’, ‘vel-
peau’ or ‘verneuil’, we searched for RCTs in the following
databases from inception until 13 August 2015: Cochrane Skin
Group Specialised Register, Cochrane Central Register of Con-
trolled Trials (CENTRAL), Medline, Embase and LILACS. We
also searched five trials registers, namely the metaRegister of
Controlled Trials (http://www.isrctn.com/page/mrct), the US
National Institutes of Health Ongoing Trials Register (www.
clinicaltrials.gov), the Australian New Zealand Clinical Trials
Registry (www.anzctr.org.au), the World Health Organization
International Clinical Trials Registry platform (www.who.int/
trialsearch) and the EU Clinical Trials Register (https://www.
clinicaltrialsregister.eu). In addition, hand searching of the
abstracts from eight international dermatology conferences was
undertaken, and bibliographies from both included and
excluded studies were examined. Two authors (J.R.I. and
A.C.K.) independently undertook study selection and no lan-
guage restrictions were applied.
Data extraction and analysis
Following piloting of our data extraction form, two pairs of
authors (J.R.I. and either P.N.W., S.L.C. or A.D.O.) indepen-
dently extracted data from the included studies and made an
assessment of methodological study quality using a Cochrane
‘risk of bias’ tool.4 The GRADE profiler (GRADEpro) was then
used to assess evidence quality for each review outcome.2
Using GRADE, evidence quality is downgraded from ‘high
quality’ by one level for each serious issue identified in the
domains of risk of bias, imprecision, indirectness, inconsis-
tency and publication bias.
© 2016 The Authors. British Journal of Dermatology
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Dichotomous outcome measures were expressed as risk ratios
and continuous outcomes were reported as mean differences.
Side-to-side, within-participant trials of topical therapies were
permitted provided that a systemic effect was unlikely and that
the left and right sides of the same anatomical site were com-
pared, because different sites may respond differently to particu-
lar interventions. Statistical heterogeneity was assessed using the
I2 statistic. We used a fixed-effects model for I2 statistic values <
40% and a random-effects model for values between 40% and
75% (there were no I2 statistic values > 75%).
Results
Description of the included studies
Our searches identified 12 trials for inclusion in the review
(Fig. 1), in which a total of 615 adults with HS
participated.5–16 The 12 trials investigated 15 different inter-
ventions and most were relatively small, with a median
number of participants of 27. In terms of trial design, eight
were parallel-group studies,5–8,10,12–14 three were within-
participant trials9,11,16 and one was a crossover study for
which we included only the first-phase data because carry-
over effects were likely.15 The median trial duration was
16 weeks.
We divided the interventions into topical therapy, systemic
therapy, surgical treatment and other therapies. Antitumour
necrosis factor-a therapies were investigated in four
studies5,10,13,14 and are classified as a subgroup of systemic
therapy.
Risk of bias in the included studies
The risk of bias for each domain across all included studies is
given in Figure 2. There was a high risk of performance bias
for within-participant laser and light studies that did not
employ a sham intervention on the untreated side.9,11,16
Detection bias was avoided for investigator-reported outcomes
in these studies by using assessors who were blinded to treat-
ment allocation; however, participant-reported outcomes
remained at high risk of bias. Two studies were at high risk
of attrition bias due to an attrition rate > 20% and lack of an
intention-to-treat analysis.12,16
Table 1 Primary and secondary outcomes of the review
Primary outcomes Secondary outcomes
1. Quality of life measured
on a validated
dermatology-specific scale
1. Participant global self-assessment
2. Adverse effects
2. Pain score
3. Physician-assessed lesion scoring
system specific to hidradenitis
suppurativa
4. Physician’s Global Assessment
5. Duration of remission (number
of days until the first new lesion
or flare)
Fig 1. Flow diagram of study selection.
© 2016 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2016) 174, pp970–978
972 Interventions for hidradenitis suppurativa: a Cochrane review, J.R. Ingram et al.
Effects of interventions
Data for the effects of interventions and the evidence quality
assessed using GRADE methodology are presented in the sum-
mary of findings tables (Tables 2–4 and Tables S1–9).
Topical therapies
Topical clindamycin vs. placebo A single trial of 30 participants
compared clindamycin 1% solution with vehicle solution for
12 weeks (frequency of application unstated).8 There was no
difference in adverse effects between the two groups, which
were reported to be mild (Table S1). SDs for the study effi-
cacy data were unavailable, preventing inclusion in the sum-
mary of findings table, and a quality-of-life outcome was not
measured. Regarding the available efficacy outcomes, there
was no difference in participant self-assessment scores
between the two groups. However, there was a significant
improvement in the HS score, a composite scale incorporating
the Participant’s Global Assessment and the number of inflam-
matory nodules, abscesses and pustules, in favour of topical
clindamycin.
Systemic therapies
Oral tetracycline vs. topical clindamycin Forty-six participants with
mild-to-moderate HS were randomized to receive either oral
tetracycline 500 mg twice daily and vehicle solution or oral
placebo and clindamycin 1% solution for 16 weeks.12 Quality
of life was not measured, but oral tetracycline did produce a
statistically significant improvement in Participant’s Global
Assessment compared with topical clindamycin (Table S2).
There was no difference in pain, number of HS lesions or
Physician’s Global Assessment. Three adverse events occurred
in the tetracycline group and five events in the topical clin-
damycin group, but the type and severity of events were not
recorded. Quality of evidence was downgraded to ‘low’ due
to attrition bias, because 12 participants did not complete the
study and were unaccounted for, and because of imprecision
from a single small study.
Ethinylestradiol and cyproterone acetate vs. ethinylestradiol and norgestrel A
12-month crossover study of 24 female participants with
moderate-to-severe HS compared ethinylestradiol 50 lg and
norgestrel 500 lg daily on days 5–25 of each menstrual
cycle with ethinylestradiol 50 lg and cyproterone acetate
50 mg on days 5–14 of each cycle.15 We included efficacy
data up to the 6-month crossover point and there was no
significant difference in Participant’s Global Assessment
(Table S3). Only 18 participants completed the study, and
thus the evidence quality was reduced to ‘moderate’ due to
imprecision.
Systemic therapies: antitumour necrosis factor-a therapies
Etanercept vs. placebo Twenty participants with active HS were
randomized to subcutaneous etanercept 50 mg twice weekly
or placebo injections for 12 weeks.5 The study reported P-
values without original trial data, and from the P-values there
were no differences between the two groups at 12 weeks in
Dermatology Life Quality Index (DLQI) scores (Table S4), Par-
ticipant’s Global Assessment, pain or Physician’s Global Assess-
ment. There were no serious adverse effects reported, only
mild injection-site reactions.
Adalimumab weekly vs. placebo One of the three arms of a placebo-
controlled trial of adalimumab therapy investigated a subcuta-
neous dose of 40 mg weekly from weeks 4 to 15, following
loading doses of 160 mg at week 0 and 80 mg at week 2.13
Fifty-one participants received weekly adalimumab and 51
were given placebo injections. The results were presented
using both last-observation-carried-forward (LOCF) and impu-
tation methods for handling missing data. At 16 weeks, adali-
mumab weekly improved the DLQI score by 40 points
compared with placebo [95% confidence interval (CI) 649
to 151, imputation method] (Table 2). Comparing the two
groups, there was no significant difference in serious adverse
events [relative risk (RR) 200, 95% CI 038–1044] or infec-
tious adverse events (RR 094, 95% CI 055–162) (Table 2).
Adalimumab weekly was superior to placebo for nearly all of
our other secondary outcomes, as well as the economic out-
come Total Work Productivity Impairment score [mean differ-
ence (MD) 1950, 95% CI 3007 to 893, imputation
method]. The study was assessed to be at low risk of bias for
all domains, but the evidence quality was reduced to ‘moder-
ate’ because it is based on only a single study and subsequent
Fig 2. ‘Risk of bias’ graph: review authors’
judgements about each ‘risk of bias’ item
presented as percentages across all included
studies.
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studies are likely to impact on our confidence in the effect
estimate and may change the estimate.17
Adalimumab every other week vs. placebo A meta-analysis of two stud-
ies was possible for several outcomes in this comparison.
Another of the three arms of the RCT described above com-
pared 52 participants given subcutaneous adalimumab 40 mg
every other week (EOW), following loading doses of 80 mg
at week 0 and 40 mg at week 1, with 51 participants given
placebo injections, reporting primary outcomes at week 16.13
A smaller study compared 15 participants given adalimumab
40 mg EOW with six participants who received placebo injec-
tions, with primary outcomes measured after 12 weeks.14
From the meta-analysis (Table 3) there was no statistically sig-
nificant difference between adalimumab EOW and placebo for
change in DLQI score (MD 161, 95% CI 386 to 064).
There was also no difference in the secondary outcomes of
pain, HS lesion score, Physician’s Global Assessment and Total
Work Productivity Impairment.
Infliximab vs. placebo One RCT of 38 participants, of whom 33
completed the trial, compared intravenous infliximab 5 mg
kg1 with intravenous placebo, reporting primary outcomes at
week 8.10 Infliximab was given in the standard dosing regi-
men, at weeks 0, 2 and 6. Infliximab improved the DLQI
score relative to placebo, with an effect size of 84 points (P
= 0003, Wilcoxon rank-sum test) (Table 4). There were two
serious adverse events in the infliximab group, a pregnancy
(outcome not reported) and hospitalization for hypertension,
compared with none for those given placebo. Infliximab
Table 2 Summary of findings: adalimumab weekly compared with placebo for hidradenitis suppurativa. Patient or population: participants with
hidradenitis suppurativa. Setting: hospital based. Intervention: adalimumab weekly. Comparison: placebo
Outcomes
Illustrative comparative risksa (95% CI)
Relative effect
(95% CI)
Number of
participants
(studies)
Quality of evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Adalimumab weekly
Change in DLQI score
(imputation). Follow-up:
16 weeks
– The mean change in
DLQI score (imputation)
in the intervention
groups was 4 lower
(649–151 lower)
– 102 (1 study) ⊕⊕⊕⊝ moderateb
Change in DLQI score (LOCF).
Follow-up: 16 weeks
– The mean change in
DLQI score (LOCF) in
the intervention groups
was 41 lower (659–
161 lower)
– 102 (1 study) ⊕⊕⊕⊝ moderateb
Frequency of serious adverse
effects. Follow-up: 16 weeks
39 per 1000 78 per 1000 (15–409) RR 200 (038–1044) 102 (1 study) ⊕⊕⊕⊝ moderateb
Frequency of treatment
discontinuation. Follow-up:
16 weeks
0 per 1000 39 per 1000c RR 5 (025–10163) 102 (1 study) ⊕⊕⊕⊝ moderateb
Proportion of participants with
infectious adverse effects.
Follow-up: 16 weeks
353 per 1000 332 per 1000 (194–572) RR 094 (055–162) 102 (1 study) ⊕⊕⊕⊝ moderateb
Proportion with improvement in
pain VAS. Follow-up: 16 weeks
271 per 1000 479 per 1000 (276–831) RR 177 (102–307) 96 (1 study) ⊕⊕⊕⊝ moderateb
Change in modified Sartorius
scale score (imputation).
Follow-up: 16 weeks
– The mean change in
modified Sartorius scale
score (imputation) in
the intervention groups
was 23 lower (5016
lower to 416 higher)
– 102 (1 study) ⊕⊕⊕⊝ moderateb
CI, confidence interval; DLQI, Dermatology Life Quality Index; LOCF, last-observation-carried-forward; RR, risk ratio; VAS, visual analogue
scale. GRADE Working Group grades of evidence: High quality, further research is very unlikely to change our confidence in the estimate of
effect; moderate quality, further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate; low quality, further research is very likely to have an important impact on our confidence in the estimate of effect and is likely
to change the estimate; very low quality, we are very uncertain about the estimate. aThe assumed risk is the risk in the placebo group of the
study population. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of
the intervention (and its 95% CI). bDowngraded one level for imprecision because the evidence is based on the results of a single study and
subsequent studies are likely to have an important impact on our confidence in the estimate of effect and may change the estimate.17 cDue
to the low frequency of events (0) in the control group, the corresponding risk reflects the observed events in the intervention group.
© 2016 The Authors. British Journal of Dermatology
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improved pain and Physician’s Global Assessment relative to
placebo, but there was no significant difference in the propor-
tion of participants in the two groups achieving ≥ 50%
improvement in an unvalidated ‘HS Severity Index’ score. The
evidence quality was downgraded to ‘moderate’ because of
the imprecision resulting from a single, relatively small study.
Table 3 Summary of findings: adalimumab every other week compared with placebo for hidradenitis suppurativa. Patient or population:
participants with hidradenitis suppurativa. Setting: hospital based. Intervention: adalimumab every other week. Comparison: placebo
Outcomes
Illustrative comparative risksa (95% CI)
Relative effect
(95% CI)
Number of
participants
(studies)
Quality of
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Placebo
Adalimumab every
other week
Change in DLQI score
(LOCF). Follow-up:
16 weeksb
– The mean change in
DLQI score (LOCF)
in the intervention
groups was 161
lower (386 lower
to 064 higher)
– 124 (2 studies) ⊕⊕⊕⊕ high –
Frequency of serious
adverse effects.
Follow-up: 16
weeksb
35 per 1000 52 per 1000 (9–296) RR 147 (026–844) 124 (2 studies) ⊕⊕⊕⊕ high –
Frequency of
treatment
discontinuation.
Follow-up: 16
weeksb
0 per 1000 0 per 1000 (0–0) RR 491 (024–9974) 124 (2 studies) ⊕⊕⊕⊕ high –
Proportion of
participants with
infectious adverse
effects. Follow-up:
16 weeksb
333 per 1000 533 per 1000
(190–1000)
RR 160 (057–453) 124 (2 studies) ⊕⊕⊕⊕ high –
Change in pain VAS.
Follow-up:
12 weeks
– The mean change in
pain VAS in the
intervention groups
was 1657 lower
(5528 lower to
2214 higher)
– 21 (1 study) ⊕⊕⊝⊝ lowc, d –
Proportion with
improvement in
pain. Follow-up:
16 weeks
271 per 1000 363 per 1000
(198–658)
RR 134 (073–243) 95 (1 study) ⊕⊕⊕⊝
moderated
–
Change in Sartorius
scale score (LOCF).
Follow-up: 16
weeksb
– The mean change in
Sartorius scale score
(LOCF) in the
intervention groups
was 042 SD lower
(122 lower to 037
higher)
– 124 (2 studies) ⊕⊕⊕⊝
moderatee
SMD 042
(122
to 037)
CI, confidence interval; DLQI, Dermatology Life Quality Index; LOCF, last-observation-carried-forward; RR, risk ratio; SMD, standardized
mean difference; VAS, visual analogue scale. GRADE Working Group grades of evidence: High quality, further research is very unlikely to
change our confidence in the estimate of effect; moderate quality, further research is likely to have an important impact on our confidence
in the estimate of effect and may change the estimate; low quality, further research is very likely to have an important impact on our confi-
dence in the estimate of effect and is likely to change the estimate; very low quality, we are very uncertain about the estimate. aThe basis for
the assumed risk is the mean risk in the placebo groups of the study populations. The corresponding risk (and its 95% CI) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). bFollow-up 12 weeks for 21 partici-
pants.14 cImbalance in baseline disease severity between the two groups: downgraded due to indirectness as the results may not be of rele-
vance to the wider population. dDowngraded one level for imprecision because the evidence is based on the results of a single study (for
each of these outcomes) and subsequent studies are likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.17 eDowngraded one level for inconsistency as the I2 statistic of 59% demonstrates substantial study heterogeneity for this
outcome.
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Surgical interventions
Gentamicin sponge vs. primary closure alone Two hundred participants
with HS undergoing excision of symptomatic lesions were
randomized to insertion of a gentamicin–collagen sponge
prior to closure or primary closure alone.7 Assessment of sur-
gical complications found no difference between the groups at
week 1 (RR 078, 95% CI 058–105) or after 3 months (RR
090, 95% CI 050–162) (Table S5). The duration of remis-
sion, measured by the recurrence rate at 3 months, was not
significantly altered by addition of the gentamicin sponge (RR
096, 95% CI 068–134). The evidence quality was down-
graded to ‘moderate’ due to an unclear risk of bias in most
domains, including an imbalance in randomization due to
early study cessation.
Other interventions
Intense pulsed light vs. no treatment A within-participant trial ran-
domized 17 participants to intense pulsed light treatment of
one side of a bilaterally affected region, compared with no
treatment of the other side.11 Twelve participants underwent
treatment of the axilla, four had groin involvement and one
had inframammary disease. Treatment-related pain caused one
participant to withdraw (treatment site unknown). Participant
treatment satisfaction was measured with an unvalidated Likert
scale and we defined treatment success as ratings of good,
excellent or clear compared with baseline. Overall, intense
pulsed light provided better participant satisfaction than no
treatment (RR 967, 95% CI 210–4643) (Table S6); how-
ever, the evidence quality was downgraded to ‘low’ due to
performance bias and imprecision.
Neodymium-doped yttrium aluminium garnet laser vs. topical control A trial
of neodymium-doped yttrium aluminium garnet (Nd:YAG)
laser therapy included 34 bilaterally affected anatomical sites
in 22 participants.16 One side of each site was randomized to
receive four laser treatments at monthly intervals, as well as
topical antimicrobials, and the other side received topical
antimicrobial therapy alone. At 3 months, results were avail-
able for 25 anatomical sites (11 groin, 10 axillary, four infra-
mammary) in 17 participants. Forty per cent of participants
reported laser-treatment-related pain, but none withdrew from
the trial as a consequence. Using the modified HS Lesion, Area
and Severity Index (HS-LASI) severity score, there was signifi-
cant benefit from Nd:YAG laser therapy for all treated sites
combined at 3 months (MD 1403, 95% CI 1884 to
922 points), and after a further 2 months of observation
(Table S7).18 However, the evidence quality was downgraded
to ‘very low’ due to the high risk of performance bias and
attrition bias, and also imprecision.
Niosomal methylene blue gel photodynamic therapy vs. free methylene blue gel
photodynamic therapy A within-participant trial compared nioso-
mal methylene blue gel photodynamic therapy with free
methylene blue gel photodynamic therapy given once every
2 weeks for up to 6 months.9 In the 10 participants who
received treatment, niosomal methylene blue gel produced a
significantly larger improvement in HS-LASI score than free
methylene blue gel (MD 430, 95% CI 836 to 024)
(Table S8). The evidence quality was downgraded to ‘low’
due to a high risk of performance bias and imprecision.
Staphage lysate vs. placebo broth Thirty-one participants were ran-
domized to receive staphage lysate both subcutaneously and as
an inhaled aerosol, or vehicle broth via the same administra-
tion routes, once weekly for 20 weeks.6 Staphage lysate is
designed to induce an immunological response and was
obtained by bacteriophage lysis of Staphylococcus aureus. No
serious adverse events occurred in either group. Based on a
Table 4 Summary of findings: infliximab compared with placebo for hidradenitis suppurativa (HS). Patient or population: participants with HS.
Setting: hospital based. Intervention: infliximab. Comparison: placebo
Outcomes
Illustrative comparative risksa (95% CI)
Relative effect
(95% CI)
Number of
participants
(studies)
Quality of
evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Infliximab
At least 50% decrease in HS
Severity Index. Follow-up:
8 weeks
56 per 1000 267 per 1000 (33–1000) RR 480 (06–3848) 33 (1 study) ⊕⊕⊕⊝ moderateb
Physician’s Global
Assessment. Follow-up:
8 weeks
167 per 1000 800 per 1000 (277–1000) RR 480 (166–139) 33 (1 study) ⊕⊕⊕⊝ moderateb
CI, confidence interval; RR, risk ratio. GRADE Working Group grades of evidence: high quality, further research is very unlikely to change
our confidence in the estimate of effect; moderate quality, further research is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate; low quality, further research is very likely to have an important impact on our confidence in
the estimate of effect and is likely to change the estimate; very low quality, we are very uncertain about the estimate. aThe assumed risk is
the risk in the placebo group of the study population. The corresponding risk (and its 95% CI) is based on the assumed risk in the compar-
ison group and the relative effect of the intervention (and its 95% CI). bDowngraded one level for imprecision due to a small number of
events in only a single study.
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Physician’s Global Assessment grading of ‘improved’, staphage
lysate was of greater benefit than placebo broth (RR 625,
95% CI 168–2327) (Table S9). The evidence quality was
downgraded to ‘moderate’ due to imprecision.
Discussion
Our review has highlighted a relative lack of high-quality evi-
dence to guide treatment decisions in HS. Only 12 RCTs with
a total of 615 participants met our inclusion criteria, whereas
the recent Cochrane review update for vitiligo, a condition
with a similar prevalence, contained 96 trials and 4512 partic-
ipants.19 Many of the RCTs included in our HS review are
small, with a median of 27 participants, and most interven-
tions were investigated by only a single RCT. As a result, evi-
dence quality had to be downgraded using GRADE
methodology for most comparisons due to imprecision, limit-
ing our clinical practice recommendations. For example, we
did not find sufficient high-quality evidence to determine the
effects of topical clindamycin or oral tetracycline, which are
standard therapies for mild-to-moderate HS.20,21
Four relatively recent RCTs of antitumour necrosis factor-a
therapies included our primary outcome of quality of life. The
results suggest that adalimumab 40 mg weekly improves qual-
ity of life compared with placebo, with a reduction in DLQI
score of 40 points, which is equivalent to the minimal clini-
cally important difference for the scale.22 However, the 95%
CI includes an effect size of only 15 points, which may repre-
sent an insufficient clinical response. There was no significant
difference in serious or infectious adverse effects compared
with placebo, but any rare or delayed adverse effects of
weekly adalimumab are currently unknown because psoriasis
biological registers provide data only for EOW dosing.23
Another issue is the higher cost of weekly treatment compared
with EOW therapy. The available evidence suggests that adali-
mumab EOW and etanercept 50 mg twice weekly are ineffec-
tive for HS. A single trial of infliximab providing efficacy data
for 33 participants reported a DLQI reduction of 84 points
relative to placebo, which is likely to be clinically relevant,
but imprecision is a limiting factor due to the small number
of participants.
Our review demonstrates a need for more surgical trials to
improve HS care; in particular there are no RCTs investigating
the timing of surgery or type of surgical procedure. We iden-
tified one trial of insertion of a gentamicin sponge wound-
healing adjuvant prior to primary closure, but this showed no
benefit compared with primary closure alone.
Based on the RCT evidence available, laser and light thera-
pies cannot be recommended for HS because the within-par-
ticipant trial designs did not incorporate a sham intervention,
which, combined with imprecision, led to downgrading of
GRADE evidence quality. It is difficult to draw conclusions
from the crossover trial investigating two endocrine interven-
tions because of the small study size and lack of placebo
control. Regarding staphage lysate, there have been no fur-
ther trials since one small RCT was performed in 1987,
resulting in insufficient evidence to recommend a change in
practice.
The recent HS Priority Setting Partnership (PSP)24 ranked
trials of oral therapies as the most important research priority,
and our review has highlighted a lack of RCT evidence in this
area, including an absence of RCTs investigating oral
immunomodulators and retinoids, and only one RCT of oral
antibiotic therapy. In line with HS PSP priorities, we found no
trials investigating treatment of an acute flare or HS-associated
pain management, and only one surgical trial. It will be
important for the design of future trials to improve validation
of HS outcome measures because many of the instruments
employed by our included studies remain unvalidated and
there is a lack of consensus regarding which outcomes to use.
There is hope for the future because our review identified
eight ongoing HS RCTs in trial registers that have not yet been
published in full. Interventions currently under investigation
include topical antiseptics, the Nd:YAG and CO2 lasers, ana-
kinra, novel biological therapies, and the PIONEER I and II
studies of adalimumab therapy. Results from these studies will
be incorporated into the planned update to our review.
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